Key Takeaways
- Sequential rebound, YoY still down: Revenue grew +13% QoQ and the company returned to profitability, but revenue remained 9% lower YoY, weighed by the absence of Zoetis revenue and a Discovery Services decline.
- Discovery is the problem child: Client attrition, commoditization pressure from Chinese and Indian CROs, and pharma R&D spending cuts hit the Discovery business, prompting a strategic repositioning from FTE to fee-for-service that will take time to convert into growth.
- CDMO fills the Zoetis hole, with a catch: Growth in the rest of the CDMO business offset the lost Zoetis/Librela revenue, but that product was high-margin, so its absence still had an impact on lower gross margin.
- Bayview lands its first deal: The U.S. biologics facility signed its first manufacturing agreement with a large pharma customer, a validation milestone, though commercial supplies remain years away pending regulatory approval.
- What to watch next quarter: Whether Discovery Services shows early signs of client re-additions under the new integrated leadership, the pace of cost-optimization benefits flowing through to margins, and any clarity on whether the maintained EBITDA guidance includes or excludes FX hedge losses.
Discovery Services: The Core Problem
- Client attrition hit capacity: Attrition at the start of the first half left enough lab capacity and bench strength to add more customers, but the revenue hole has not yet been filled.
- Commoditization pressure: Large CROs in China and emerging CROs in India are competing on price in traditional FTE-based discovery work, squeezing Syngene's positioning.
- Pharma R&D cuts an external drag: Some business attrition is attributed to large R&D spending downsizing announced by pharma companies themselves, an industry headwind beyond Syngene's control.
- Strategic repositioning underway: The business is shifting from a predominantly FTE model to a fee-for-service, value-add model embedding AI, automation, and digital technologies; the integration of Discovery Biology and Discovery Chemistry under unified scientific leadership took effect October 1.
- Turnaround is not overnight: Management flagged that the transformation from execution-led to intelligence-driven platform will need more time to translate into revenue growth; key monitorables are new client additions, new projects onboarded, and molecules progressed from discovery to development.
Mittal: "Discovery will continue to be a very core part of our overall journey, but we will redo the way we have -- I mean, traditionally it's been more an FTE business, and what we are looking at is embedding AI to make it more fee-for-service, FFS value-add business."
CDMO & the Zoetis Overhang
- Zoetis absence the YoY drag: The loss of Zoetis/Librela revenue was the primary driver of the 9% YoY revenue decline; it was a high-margin product, so its absence also impacted gross margin from the manufacturing segment.
- Rest of CDMO grew: Growth in the broader CDMO portfolio made up for the Zoetis gap on the topline, though not on the margin line.
- Zoetis facility locked until next fiscal year: The Biocon Park biologics facility that supported Zoetis is U.S. FDA approved but cannot manufacture for any other customer until next fiscal year; it will manufacture batches for Zoetis in H2 FY27 for Q4 delivery, and the capacity becomes available for a new customer only after that.
- Gross margin mix effect: Gross margin is calculated as revenue less material cost, which applies only to the CDMO business; research carries fixed people and lease costs, so the shift of revenues from Discovery to Development distorts quarter-to-quarter gross margin comparisons. On an absolute basis, CDMO gross margins are at similar levels, though the Zoetis absence did lower them.
- Hedge losses persist: A foreign exchange hedge loss of INR61 crore hit this quarter, and similar hedge losses are expected in H2 FY27 from forward contracts tied to one large dedicated customer contract that runs until FY28.
- Hedge policy changing: Syngene is moving from forward contracts to options; once current hedges expire in FY28, the sustainable level of gross margins is already in the mid-20s.
Mittal: "But on a more sustainable basis, I think I would definitely draw your attention that hedge losses, we have changed our hedge policy and we will start moving towards more the options rather than forward contracts. And once the current hedges get over, which will be in FY '28, the sustainable level of gross margins, we are already in mid-20s."
Bayview & Biologics: The Growth Bet
- First manufacturing agreement signed: The Bayview Biologics facility in the United States secured its first contract with a large pharmaceutical customer, a validation milestone for the asset.
- Timeline is long: Process development begins in India during FY27; drug substance manufacturing at Bayview is scheduled to start in FY28; the product is not yet commercially approved, so commercial supplies will depend on regulatory approval, expected in the second half of calendar 2028 at best.
- Pre-operative expenses: Capitalization of Bayview expenses will continue until first regulatory approval, with the best-case timeline pointing to H2 CY28.
- Utilization questions unanswered: Management did not disclose what utilization the first contract represents or when peak utilization might occur, describing the deal as a first step and asking for more time.
- Unit 3 adding clinical contracts: The Bangalore biologics facility, Unit 3, secured a clinical supply agreement with an existing partner, the latest in a series of contracts; management confirmed multiple customers are signed on but did not disclose whether this specific contract is with the same partner as earlier CMO arrangements.
- Biologics demand seen as strong: Management sees huge capacity demand for biologic manufacturing, with the BIOSECURE Act adding advantage, and aims to be the Indian CRDMO of choice to capture share currently going to Korean players.
Mazumdar-Shaw: "I would go so far as to say that the capacity demand for biologic manufacturing is huge. And I think right now, the ones who are capturing that opportunity are the Koreans. We would like to be the Indian company of choice, the Indian CRDMO of choice to really basically take advantage of this demand."
Margins & Cost Optimization
- Sequential margin improvement: Operating EBITDA margin improved six percentage points QoQ to 18%, driven by higher revenues, improved operating leverage, and initial benefits of cost optimization initiatives.
- YoY margin still deeply down: EBITDA margin was lower by 22% reported in Q2 of last year, reflecting lower revenues from Librela and the INR61 crore FX hedge loss.
- Manpower optimization complete: Cost actions on the manpower side have been completed; initiatives targeting other operating expenses remain underway, with benefits expected to become progressively more visible over coming quarters.
- SG&A improvement: The quarter's SG&A cost improvement reflects cost initiatives from the last two quarters; management endeavors to sustain expenses at current levels and expects additional benefits in H2.
- Organizational restructuring done: Most of the planned reorganization is complete, with some additional capability onboarding still to come; management described it as a surgical right-sizing after the organization had become inefficient with extra costs from people without defined roles.
- Return to profitability: The company reported a PAT of INR32 crore versus a loss of INR9 crore in the previous quarter, though an exceptional charge of INR6 crore net of tax was recognized for employee termination benefits.
Mazumdar-Shaw: "Well, let me answer that by saying that every organization has to bite the bullet and do what is right for the organization. Fortunately, we have a very deep pipeline of talent in Syngene. And we have very, very good scientific talent at that."
Strategic Shifts: FTE to FFS, AI & New Modalities
- FTE to FFS model change: Syngene is repositioning from selling FTEs to selling scientific outcomes; the logic is that using AI and automation to reduce the number of FTEs deployed lets the company charge a premium, because the real science is in how few FTEs are needed.
- AI and automation investments: ChemVoyager, an AI-enabled synthesis planning platform, has been implemented alongside automated analytical systems and end-to-end sample tracking; further investments in AI, automation, and digitalization are planned for Discovery Services in coming quarters.
- New modalities in small molecules: The company is focusing on peptides and oligonucleotides rather than traditional small molecules, where other Indian CMOs are more cost-competitive or have larger capacities; a technically complex siRNA oligonucleotide manufacturing program was successfully completed at GMP level for a leading global pharma company.
- End-to-end integration ambition: Management is confident that over time, Syngene will add many more programs where molecules enter at discovery and advance through development to commercial manufacturing; the commercial team will showcase these end-to-end capabilities.
- ADC conjugation capability: Syngene claims to be the only company fully integrated from biologic to linker to payload and conjugation at commercial scale.
- New translational science lab: A clinical translational science laboratory was commissioned in Bangalore, expanding capabilities in biomarkers, precision medicine, biobanking, and bioanalysis; the investment is not very large.
Mittal: "So while you might have a lower FTE rate or a higher FTE rate, how many FTEs you're deploying is the real science. Because if you use technology, AI automation, and reduce the number of FTEs, then customers are willing to pay you premium. And that's the change in model that we are talking about."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin guidance | Maintained at mid-20s; management wants to wait another quarter before any change | FY27 |
| Hedge losses in H2 | Similar level of FX hedge losses expected as in H1, from forward contracts on one large dedicated customer contract | Through FY28 |
| Bayview process development | Process development activities to commence in India | FY27 |
| Bayview drug substance manufacturing | Manufacturing to begin at the U.S. facility | FY28 |
| Bayview commercial supplies | Dependent on regulatory approval of the customer's product | Best case H2 CY28 |
| Bayview expense capitalization | Pre-operative expenses capitalized until first regulatory approval | Until H2 CY28 (best case) |
| Zoetis facility third-party use | Facility cannot manufacture for any other customer | Until next fiscal year |
| Sustainable gross margins | Mid-20s level already achieved on a sustainable basis, once current hedges expire | FY28 |
| SG&A expenses | Endeavor to sustain at current levels, with additional benefits from cost initiatives | H2 FY27 |
| Organizational restructuring results | Results of the restructuring and integrated model to become visible | Next two quarters |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹833 cr, +13% QoQ, -9% YoY (absence of Zoetis revenue) |
| Discovery Services revenue share | 65% of quarterly revenue |
| CDMO revenue share | 35% of quarterly revenue |
| Operating EBITDA | ₹147 cr |
| Operating EBITDA margin | 18%, +6 ppt QoQ; adjusted for FX hedge loss would be mid-20s |
| Foreign exchange hedge loss | ₹61 cr, booked during the quarter |
| Profit after tax (before exceptional item) | ₹38 cr |
| Exceptional charge (employee termination benefits, net of tax) | ₹6 cr |
| Reported profit after tax | ₹32 cr, vs loss of ₹9 cr in Q1 FY27 |
| Capital investment (H1 FY27) | ~₹200 cr, directed toward Bayview, automation, infrastructure |
| Net cash position | ₹1,392 cr at quarter end |
| Bayview pre-operative expenses capitalized (H1 FY27) | ₹66 cr |
| CDMO business YoY decline | ~2-3% (per an analyst's math), Discovery decline the larger driver of YoY revenue change |
| Zoetis/Librela supply obligation | Back-end loaded in Q4 FY27 |
| Biologics manufacturing capacity | 50 KL ready capacity |